WHY IT MATTERS: Patients purchasing hemp-derived products in Alabama and other states with limited oversight may be unknowingly consuming products with inaccurate THC levels or harmful contaminants, which poses real risks to health and undermines therapeutic goals. CLINICAL OVERVIEW: Unregulated hemp-derived products have long occupied a legal gray zone where labeling claims frequently diverge from actual contents, and third-party testing has repeatedly revealed discrepancies in cannabinoid concentrations alongside contamination with mold, pesticides, and carcinogenic compounds. Alabama’s new THC limits for hemp products reflect a broader regulatory trend of states stepping in to fill the vacuum left by federal inaction on consumer safety standards for this category.